Ongoing Novel Immunotherapy Trial Builds on PACIFIC Benefits in Stage III NSCLC
Dan Costin, MD, discusses his strategies for patients with early-stage lung cancer and ongoing trials that could improve outcomes even further.
Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC
David R. Gandara, MD, discusses the benefit of nivolumab and ipilimumab in combination with chemotherapy in metastatic non–small cell lung cancer.
Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC
Howard (Jack) West, MD, discusses the use of nivolumab in combination with ipilimumab in metastatic non–small cell lung cancer.
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
2 Clarke Drive Cranbury, NJ 08512